Ispecimen Inc. · NASDAQ:ISPC
Ispecimen — Investor Presentation (May 2022)
29 slides from Ispecimen's investor presentation, May 10, 2022
Slide 1: Transforming Biospecimen Procurement
CONNECT. INNOVATE. May 2022 Investor Presentation TRANSFORMING BIOSPECIMEN PROCUREMENT An online marketplace for human biospecimens
Slide 2: Forward-looking statements
This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as “may,” “w
Slide 3: Management team
Christopher Ianelli, MD, PhD| Chief Executive Officer, President, and Director Dr. Ianelli has been serving as our Chief Executive Officer, President, and Director since founding iSpecimen in July 2009. Dr. Ianelli served as Chief Executive Officer of Abkine Pharmaceuticals, Inc. Dr. Ianelli served
Slide 4: Investor Highlights
Investor Highlights 4 >200 Healthcare Provider / Supplier Organizations >430 Customer Organizations 1. Early-stage opportunity with a first mover advantage 2. $3B-$4B global biospecimen market growing at 10-15% per year1 3. Unique two-sided marketplace disrupting the biospecimen procurement process
Slide 5: Our Vision
Accelerate scientific discovery via an online marketplace that empowers researchers to instantly search for and gain access to patients, biospecimens, and data across a global network of healthcare providers Our Vision 5
Slide 6: Human Biospecimens are Essential for Life Science R&D
Human Biospecimens are Essential for Life Science R&D Basic Research Biomarker Identification & Validation Drug Discovery & Development Diagnostics Discovery & Validation Biofluids Solid Tissue Stem & Immune Cells Plasma, Serum, Urine, Saliva Industry Academia Government 6 Lung, Breast, Colon, Brain
Slide 7: Large and Inefficient Biospecimen Market
10 - 15% Annual Growth Fueled by precision and regenerative medicine research 2 Disconnected Market Participants in Need of a Marketplace Solution With an Inefficient Supply Chain Manual processes plus fragmentation make it ripe for an online marketplace solution Large and Inefficient Biospecimen Ma
Slide 8: Market Inefficiencies
Market Inefficiencies PROVIDER RESEARCHER Scientist / Informaticist Procurem ent Legal & Compliance IT / Informaticist Scientist & Informaticist Legal & Compliance IT / Informaticist Researcher & Procurement Legal & Compliance Principal Investigator & Specimen Operations PATIENTS PROVIDERS RESEARCHE
Slide 9: Inefficiencies Lead to Losses
Inefficiencies Lead to Losses Providers miss revenue and research opportunities > 3 Billion clinical specimens are discarded annually worldwide 5 > 1 Billion Patient encounters yearly in the U.S. where a specimen could be provided for research 4 > 800 Million banked specimens are in biorepository in
Slide 10: The iSpecimen Marketplace Solution
The iSpecimen Marketplace® Solution 10 PROVIDER Procurement Principal Investigator / Operations IT / Informaticist PATIENTS Legal & Compliance IT / Informaticist Researcher & Procurement Legal & Compliance Principal Investigator & Specimen Operations Scientist & Informaticist Blood / Pheresis Center
Slide 11: Full-Service Procurement
Full-Service Procurement We Not Only Connect Suppliers and Customers, but Also Manage the Entire Procurement Process SPECIMEN SEARCH & SELECTION SPECIMEN LOGISTICS SPECIMEN MANAGEMENT DATA MANAGEMENT STUDY/ORDER MANAGEMENT SUPPLIER SITE TRAINING COLLECTION KIT BUILDING COMPLIANCE MANAGEMENT STUDY DE
Slide 12: Suppliers and Researchers Benefit
Suppliers and Researchers Benefit Advance Discovery Support research mission and advance diagnostic, therapeutic, and vaccine research Increase Revenue Instantly connect to a global network of researchers Ensure Compliance On a platform that protects the privacy and security of patient information A
Slide 13: Growing Supplier Adoption
13 34 66 102 147 181 200 205 Growing Supplier Adoption 1000+ Hospitals Also includes two Healthcare Information Exchanges 55% CAGR Number of Suppliers (2015 – March 31, 2022) WORLDWIDE COVERAGE United States United Kingdom Germany France Ukraine Georgia Bulgaria Russian Federation India Peru Dominic
Slide 14: Growing Researcher Adoption
$700 $1,448 $3,067 $4,395 $4,298 $8,184 $11,135 $2,519 Cumulative Customer Organizations with Purchases 2015 – March 31, 2022 59% CAGR Customers (2015 – March 31, 2022) Annual Revenue ($000) - Unaudited 2015-18, 2022 2015 – March 31, 2022 59% CAGR Revenue (2015 – 2021) Growing Researcher Adoption 70
Slide 15: Growing Marketplace Adoption
80 118 668 1,587 2,681 3,871 5,218 5,631 Cumulative Researcher and Supplier Marketplace Users 2015 – March 31, 2022 98% CAGR Registered Users (2015 – March 31, 2022) Growing Marketplace Adoption ~4,400 Unique searches performed by researchers in the iSpecimen Marketplace in 2021 ~65% % of suppliers
Slide 16: Growing Data Asset
“Utilization of sample data for research and for monetization is the next key value driver for the biobanks.” - Frost & Sullivan, Global Biobanking Market Landscape Growing Data Asset Banked Specimen Records Patient Records Medical Condition Records Clinical Specimen Records Laboratory Test Records
Slide 17: Statement of Operations (Unaudited)
Statement of Operations (Unaudited) 17 2022 2021 Revenue 2,518,660 $ 2,963,807 $ Operating expenses: Cost of revenue 1,165,917 1,623,651 Technology 527,522 409,951 Sales and marketing 747,432 529,387 Supply development 182,070 111,576 Fulfillment 443,794 269,096 General and administrative 1,810,313
Slide 18: Balance Sheet
Balance Sheet 18 March 31, 2022 December 31, 2021 (Unaudited) Assets Cash 26,099,178 $ 27,738,979 $ Accounts receivable - unbilled 1,258,515 1,739,020 Accounts receivable, net of allowance 2,356,688 3,002,442 Prepaid expenses and other current assets 295,750 327,035 Tax credit receivable, net of cur
Slide 19: Fully Diluted Shares of Common Stock Outstanding
Fully Diluted Shares of Common Stock Outstanding Diluted Common Shares Shares outstanding at March 31, 2022 8,814,283 Shares issuable upon vesting of restricted stock units 291,167 Shares issuable upon exercise of stock options 176,142 Shares issuable upon exercise of PIPE Warrant to purchase common
Slide 20: Investor Summary
Investor Summary 20 >200 Healthcare Provider / Supplier Organizations >430 Customer Organizations 1. Early-stage opportunity with a first mover advantage 2. $3B-$4B global biospecimen market growing at 10-15% per year 3. Unique two-sided marketplace disrupting the biospecimen procurement process 4.
Slide 21: Contact Us
CONNECT. INNOVATE. Sign up for free iSpecimen Marketplace account at www.ispecimen.com CONTACT US iSpecimen Inc. 450 Bedford Street Lexington, MA 02420 investors@ispecimen.com ispecimen.com
Slide 22: Appendix
Appendix 22
Slide 23: Strategic Evolution
Strategic Evolution PHASE 3 Expansion via the Online iSpecimen Marketplace™ START UP Company Ideation and Self- Funding PHASE 1 Proof of Concept PHASE 2 Critical Mass of Suppliers and Early Customer Adoption 2010 – 2011 2012 – 2013 2014 – 2017 2018 – 2021 0 Customers 1 Supplier Agreement 0 Specimen
Slide 24: iSpecimen Marketplace UI/UX
iSpecimen Marketplace UI/UX Click Search to start searching for specimens 24
Slide 25: iSpecimen Marketplace UI/UX
25 iSpecimen Marketplace UI/UX Use search bar to quickly find specimens that match search criteria
Slide 26: Refine Search Results Using Sliders and Check Boxes
Refine Search Results Using Sliders and Check Boxes iSpecimen Marketplace UI/UX 26
Slide 27: View Quote Request and Add More Specimens
View Quote Request and Add More Specimens Request a Quote iSpecimen Marketplace UI/UX 27 Track and Manage Requests
Slide 28: Sources Cited
28 Page Note Source Cited 7 1 iSpecimen estimates based on In Vitro Diagnostics Market Size, Share & Trends Analysis Report By Product, By Application, By Technology (Immunochemistry, Molecular Diagnostics) By End-use, By Region, And Segment Forecasts, 2021 – 2027. Grandview Research, January 2021;
Slide 29: @ iSPECIMEN
@ iSPECIMEN Market i